{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:15:45Z","timestamp":1793988945374,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["C04-110028"],"award-info":[{"award-number":["C04-110028"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["D-109063"],"award-info":[{"award-number":["D-109063"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.amjoto.2021.103156","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T12:31:30Z","timestamp":1624624290000},"page":"103156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Oral tegafur-uracil as a metronomic therapy in stage IVa and IVb cancer of the oral cavity"],"prefix":"10.1016","volume":"42","author":[{"given":"Wen-Yen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Liang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Yi","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jih-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjoto.2021.103156_bb0005","first-page":"7","article-title":"An overview of detection and screening of oral cancer in Taiwan","volume":"18","author":"Kao","year":"2015","journal-title":"Chin J Dent Res"},{"key":"10.1016\/j.amjoto.2021.103156_bb0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age\u2013sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.amjoto.2021.103156_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053415","article-title":"Survival of patients with oral cavity cancer in Germany","volume":"8","author":"Listl","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.amjoto.2021.103156_bb0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1744-8603-1-14","article-title":"The health impacts of globalisation: a conceptual framework","volume":"1","author":"MMTE","year":"2005","journal-title":"Glob Health"},{"key":"10.1016\/j.amjoto.2021.103156_bb0025","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/1097-0142(19850915)56:6<1242::AID-CNCR2820560603>3.0.CO;2-Z","article-title":"Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy","volume":"56","author":"Hong","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.amjoto.2021.103156_bb0030","first-page":"32","article-title":"Expanding role of the medical oncologist in the management of head and neck cancer","volume":"58","author":"Choong","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.amjoto.2021.103156_bb0035","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","article-title":"Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study","volume":"28","author":"Perry","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjoto.2021.103156_bb0040","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.bjc.6605412","article-title":"Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study","volume":"101","author":"Reardon","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjoto.2021.103156_bb0045","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.2008.18.3939","article-title":"Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for breast Cancer 01 trial","volume":"27","author":"Watanabe","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjoto.2021.103156_bb0050","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa032792","article-title":"A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung","volume":"350","author":"Kato","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjoto.2021.103156_bb0055","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jhep.2010.01.035","article-title":"Phase II study of combining sorafenib with metronomic tegafur\/uracil for advanced hepatocellular carcinoma","volume":"53","author":"Hsu","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjoto.2021.103156_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000336126","article-title":"Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma","volume":"82","author":"Shao","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.amjoto.2021.103156_bb0065","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00280-006-0377-4","article-title":"Biweekly oxaliplatin plus 1-day infusional fluorouracil\/leucovorin followed by metronomic chemotherapy with tegafur\/uracil in pretreated metastatic colorectal cancer","volume":"60","author":"Lin","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.amjoto.2021.103156_bb0070","first-page":"2605","article-title":"Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma","volume":"27","author":"Ogata","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.amjoto.2021.103156_bb0075","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1158\/1078-0432.CCR-08-3317","article-title":"Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer","volume":"15","author":"Fontana","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjoto.2021.103156_bb0080","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.juro.2007.01.143","article-title":"Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study","volume":"177","author":"Lord","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.amjoto.2021.103156_bb0085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1470-2045(09)70383-3","article-title":"Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)","volume":"11","author":"Bellmunt","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjoto.2021.103156_bb0090","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjoto.2021.103156_bb0095","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjoto.2021.103156_bb0100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjoto.2021.103156_bb0105","first-page":"91","article-title":"Irinotecan and UFT\/leucovorin in patients with advanced cancers","volume":"14","author":"Stevenson","year":"2000","journal-title":"Oncology"},{"key":"10.1016\/j.amjoto.2021.103156_bb0110","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jds.2015.03.004","article-title":"Oral uracil and tegafur as postoperative adjuvant metronomic chemotherapy in patients with advanced oral squamous cell carcinoma","volume":"10","author":"Lin","year":"2015","journal-title":"J Dental Sci"},{"key":"10.1016\/j.amjoto.2021.103156_bb0115","first-page":"105","article-title":"Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"104547","author":"Hanahan","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjoto.2021.103156_bb0120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clon.2013.01.002","article-title":"Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers","volume":"25","author":"Patil","year":"2013","journal-title":"Clin Oncol"},{"key":"10.1016\/j.amjoto.2021.103156_bb0125","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/01.mph.0000183863.10792.d4","article-title":"A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive disease. Cancer","volume":"27","author":"Kieran","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.amjoto.2021.103156_bb0130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","article-title":"Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance","volume":"358","author":"Kareva","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.amjoto.2021.103156_bb0135","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/ijc.28259","article-title":"Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells","volume":"133","author":"Vives","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.amjoto.2021.103156_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPH.0b013e3182024918","article-title":"Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?","volume":"33","author":"Klement","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.amjoto.2021.103156_bb0145","article-title":"Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer","volume":"12","author":"Huang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.amjoto.2021.103156_bb0150","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1002\/hed.25904","article-title":"Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma","volume":"41","author":"Chen","year":"2019","journal-title":"Head Neck"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019607092100257X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019607092100257X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:08:59Z","timestamp":1759295339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019607092100257X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S019607092100257X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2021.103156","relation":{},"ISSN":["0196-0709"],"issn-type":[{"value":"0196-0709","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral tegafur-uracil as a metronomic therapy in stage IVa and IVb cancer of the oral cavity","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2021.103156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103156"}}